
ãªã¡ã¬3ã飲ãã ã»ããããã®ãåé¡ã«å€§ããªãã³ããåºã
ãã£ãã·ã¥ãªã€ã«ãæã®èªåã¯ã¡ãã£ãšåãæãããã¿ããã«é£²ãã§ããã
è³ã«ãããäžæ§èèªãäžãããããããããããããããè«æãèªããã³ã«ãããã¯é£²ãŸãªããšæããšæã£ãŠããææãããã
ã§ãä»ã¯é£²ãã§ããªãã
ãå çããã£ãã·ã¥ãªã€ã«ã£ãŠé£²ãã ã»ããããã§ããïŒã
倿¥ã§ãããèãããé »åºŠããã¶ãæã«3åã¯ãããèªåããã£ãšã¢ã€ã¢ã€ããŠããããªã¡ã¬3ãå¹ããšããç ç©¶ãšå¹ããªããšããç ç©¶ã亀äºã«åºãŠããŠãäœå¹Žããçµå±ã©ã£ã¡ãªãããããç¶æ ãç¶ããŠããã
2019幎ã®å€§èŠæš¡ãªèšåºè©Šéšã§ã¯å¿èã€ãã³ã25%æžãšããæŽŸæãªçµæãåºããäžæ¹ãç¿å¹Žã®è©Šéšã§ã¯ãŸã£ããã®å¹æãªãã
å»è å士ã§ãæèŠãå²ããããŒãã ã£ãã
ããã«2025幎æ«ãNEJMããããªã倧ããªããŒã¿ãåºãŠãããéææ£è ã«ãã£ãã·ã¥ãªã€ã«ãæ¯æ¥é£²ãã§ããã£ããå¿èã®é倧ã€ãã³ããå€§å¹ ã«æžã£ãããšãã話ïŒNEJM 2026幎1æå·ïŒã
ãã®PISCES詊éšã®çµæãšãèŠèœãšããªãäžæŽèãªã¹ã¯ãæè¿ã®ãè³ã«ãå¹ãã®ããã確ããã詊éšããããŠãèªåã«ãšã£ãŠæå³ããããããã©ã枬ãããŸã§æžããããšãå»è ã®èªåããªãã§é£²ãã®ããããã®ãããã®çç±ããæåŸã«æžãã
ã©ããªç ç©¶ã ã£ãã®ãïŒPISCES詊éšïŒ
3幎åãã£ãã·ã¥ãªã€ã«ã飲ã¿ç¶ããéææ£è ã§ãå¿è¡ç®¡ã€ãã³ããã»ãŒååã«æžã£ãããããPISCES詊éšã®äžèº«ã ã
ãéææ£è ã®è©±ã§ããïŒããšæããããããªããã©ãããå°ãä»ãåã£ãŠã»ããããã®ç ç©¶ãããæ®éã«ãã£ãã·ã¥ãªã€ã«ã飲ãã§ãã人ã«ã䜿ãããã³ããåºãŠããã
ã«ãããšãªãŒã¹ãã©ãªã¢ã®26æœèšã§è¡ãããäºéç²æ€ã®ã©ã³ãã 忝èŒè©Šéšã察象ã¯ç¶æè¡æ¶²éæãåããŠããæäºº1,228人ã
å¹³å幎霢64æ³ã女æ§37%ã
ä»å ¥çŸ€ã«ã¯n-3ç³»èèªé žïŒïŒãªã¡ã¬3ïŒã1æ¥4gããã®ãã¡å¿èãžã®å¹æãæåŸ ããã宿åEPA+DHAãåèš2.4gïŒEPA 1.6gïŒDHA 0.8gïŒå ¥ã£ãŠãããå¯Ÿç §çŸ€ã«ã¯ã³ãŒã³æ²¹ã®ãã©ã»ãã3.5幎é远跡ã
äºéç²æ€ã®ã©ã³ãã 忝èŒè©ŠéšïŒRCTïŒãšããã®ã¯ãæ£è ãå»è ãã©ã£ã¡ã飲ãã§ãããç¥ããªãç¶æ ã§æ¯èŒãããã¶ã€ã³ã§ããšããã³ã¹ã®è³ªãšããŠã¯ãããã¯ã©ã¹ã«ãªãã芳å¯ç ç©¶ãšã¯éã¿ãéãã
äž»èŠè©äŸ¡é ç®ã¯ãé倧ãªå¿è¡ç®¡ã€ãã³ãã®è€åããå ·äœçã«ã¯å¿èæ»ïŒçªç¶æ»å«ãïŒãå¿çæ¢å¡ãæ«æ¢¢è¡ç®¡çŸæ£ã«ããè¶³ã®åæãè³åäžãã©ããåœã«çŽçµãããããŸãããå¹ããªãè©äŸ¡é ç®ã°ããã ã
ã¡ãªã¿ã«ã以åããçµå¶è ã«ããã£ãã·ã¥ãªã€ã«é£²ãã§ããã ãããããšèšãããŠéæãèãããEPA+DHAã1ã«ãã»ã«300mgã1æ¥1ã«ãã»ã«ã詊éšã®æäžéã®8åã®1ã ã£ãã飲ãã§ãæ°åã«ã¯ãªãããã©ãç ç©¶ã§äœ¿ãããŠããéãšã¯å šç¶éããããã ãéãéã詊ããã®ãPISCES詊éšã ã
çµæïŒéææ£è ã§ãªã¹ã¯43%æžå°
ãã£ãã·ã¥ãªã€ã«çŸ€ã¯ãã©ã»ãçŸ€ã«æ¯ã¹ãŠå¿è¡ç®¡ã€ãã³ããã»ãŒååã«æžã£ããæ°åã§èŠããšãã€ãã³ãçºççã¯1,000æ£è æ¥ããããã£ãã·ã¥ãªã€ã«çŸ€0.31ããã©ã»ã矀0.61ã
ãã¶ãŒãæ¯ïŒHRïŒ0.57ïŒ95%ä¿¡é Œåºé 0.47â0.70, P<0.001ïŒã
ãã£ããèšãã°ãªã¹ã¯ã43%äœãã£ãããšããããšã«ãªãã
100人ã§èµ·ããŠããå¿èäºæ
ãã57äººã§æžãã ããšããã€ã¡ãŒãžã
å¶ç¶ã§åºãå·®ãããªãããšçµ±èšãèšã£ãŠããã
ãã ãHRã¯ãã€ãã³ãã®èµ·ããããã®æ¯ãã§ãã£ãŠãå³å¯ã«ã¯ããªã¹ã¯ãã®ãã®ããšã¯éããã€ãã³ããå°ãªãéå£ã§ã¯%衚èšã宿 ãã倧ããèŠããããšãããã®ã§ã43%ãšããæ°åã®å°è±¡ã ãã§å€æããªãã»ããããã
å¿èæ»ãå¿çæ¢å¡ãè³åäžããã©ããäžè²«ããŠæžã£ãŠããã

ãã®çµæãã©ãèªããïŒå»åž«ãšããŠã®è§£éïŒ
43%ãšããæ°åã¯ãããã«ã€ã³ãã¯ããããã
ããããå·éã«èŠãŠãããããã€ã³ããããã€ãããããŸã察象ãè¡æ¶²éææ£è
ã§ããããšãéææ£è
ã®å¿è¡ç®¡æ»äº¡çã¯äžè¬äººå£ã®10ã20åãšããããããæ
¢æ§ççã代è¬ç°åžžãå¿äžå
šå䜵ãéãªã£ã極端ãªé«ãªã¹ã¯éå£ã ã
ç ç©¶è èªèº«ããéææ£è ã¯EPA+DHAã®è¡äžæ¿åºŠãäžè¬äººããèããäœãããšææããŠãããããšããšè¶³ããŠããªã人ã»ã©ãè£å ã®å¹æãåºããããéææ£è ã¯ãã®ãè¶³ããŠããªãåŽãã«ããããšããããšã ã
ã€ãŸãããã®çµæããã®ãŸãŸå¥åº·ãªäººã«åœãŠã¯ããã®ã¯é£èºããããç ç©¶è æ¬äººãããæžããŠããã
ã©ã³ãã 忝èŒè©Šéšã ããå æé¢ä¿ã®æ¹åæ§ã¯ããªã匷ããããªã¡ã¬3ã飲ãã ããæžã£ãããšèšãããã¶ã€ã³ã«ãªã£ãŠããããã ããã®1詊éšã ãã§ãéææ£è å šå¡ã«ãã£ãã·ã¥ãªã€ã«ãããšçµè«ã¥ããã«ã¯ãè¿œè©Šãæ¬²ããã
ãããéæãããªãèªåãã¡ã«ãšã£ãŠããã®ç ç©¶ã¯äœã®æå³ãããã®ãã
ãè¯ã話ãã ãã§ã¯çµãããªãïŒå¿æ¿çްåã®ãªã¹ã¯ïŒãªã¡ã¬3ãšäžæŽèïŒ
ãããã飲ããïŒããšãªãããã ãã©ãã¡ãã£ãšåŸ
ã£ãŠã»ããã
ãªã¡ã¬3ã®ãµããªã¯ãå¿æ¿çްåïŒAFïŒã®ãªã¹ã¯ãäžãããšããå ±åãè€æ°ã®èšåºè©ŠéšããåºãŠããã
ãããŸã§ã®ç ç©¶ã䞊ã¹ããšãæ§å³ã¯ãããªã£ãŠããã
å¿è¡ç®¡ãªã¹ã¯ãæ¢ã«é«ã人ã«é«çšéãªã¡ã¬3ïŒ1æ¥1.5g以äžïŒãå ¥ãããšãå¿æ¿çްåãªã¹ã¯ãçŽ1.5åã«ãªã
äœãªã¹ã¯ã®å¥åº·ãªäººã§ã¯ãåãçšéã§ãå¿æ¿çްåäžæã¯ãªã
é£äºããæã£ãŠè¡äžæ¿åºŠãé«ã人ã¯ããããå¿æ¿çްåãå°ãªã
代衚ããŒã¿ã¯2025幎ã®34詊éšã»çŽ11äžäººã察象ã«ããææ°ã¡ã¿ã¢ããªã·ã¹ãšãUK BiobankïŒè±åœã®å€§èŠæš¡å»çããŒã¿ããŒã¹ïŒã®26äžäººè¶ ã®ã³ããŒãç ç©¶ã ã
ã€ãŸããé£äºãäžè¬çãªãµããªïŒ1ã2g/æ¥ïŒã§è¡äžãªã¡ã¬3ãé©åºŠã«ä¿ã€ããšãšãè¬å€ã¬ãã«ã®é«çšéïŒ4g/æ¥ïŒãå ¥ããããšã¯ãå¿æ¿çްåãžã®äœçšãããããéããããããå€ããã°å€ãã»ã©ãããèš³ã§ã¯ãªãããšããæ¹åã«ããŒã¿ãåæããŠããŠããã

PISCES詊éšã§ã¯æå®³äºè±¡ãšããŠå¿æ¿çްåã®ææãªå¢å ã¯å ±åãããŠããªãããã ã察象ãéææ£è ãšããç¹æ®ãªéå£ã§ããããšã¯é ã«å ¥ããŠããå¿ èŠãããã
ã¡ã«ããºã ã¯ãŸã 確å®çã§ã¯ãªãã现èèã«ãªã¡ã¬3ãåã蟌ãŸããŠèã®æããããå€ãããå¿æ¿ã®é»æ°ä¿¡å·ã«åœ±é¿ãã説ããè¿·èµ°ç¥çµåºæ¿ã匷ãã説ãåºãŠããã
åŸè
ãæå±ããO'Keefeã¯ããªã¡ã¬3ãã諞åã®å£ããšåŒãã§ããã
å¿èãå®ãæ¹åã«ããå¿æ¿çްåãèµ·ããæ¹åã«ãäœçšãããããšããããšã ãåããéãäœ¿ãæ¹ã§è¬ã«ãæ¯ã«ããªããæ§é ã¯ã以å [ãæ£ããæ¯ããäœã匷ãããââãã«ãã·ã¹ã®ç§åŠ] ã§ãæžããã
ãªã¡ã¬3ã«å¯Ÿããèãæ¹ã¯ãèªåãé«ãªã¹ã¯åŽãäœãªã¹ã¯åŽããã§ãŸãã§éãã
å¿èç ã»ç³å°¿ç ã»é«éœ¢ã»éæãªã©ã®ãªã¹ã¯ãæ¢ã«ãã人ã¯ãPISCES詊éšã®ããã«å¿è¡ç®¡ã€ãã³ãã倧ããæžãããå¯èœæ§ãããäžæ¹ã§ãå¿æ¿çްåãªã¹ã¯ãäžãããã¡ãªãããšãªã¹ã¯ã®äž¡æ¹ã倩秀ã«ããã話ã«ãªããããèªå·±å€æã§ã¯ãªã䞻治å»ãšçžè«ããŠåå¥ã«æ±ºããé åã ã
å¥åº·ãªäœãªã¹ã¯åŽã®äººã«ã¯å¿æ¿çްåäžæã®ã·ã°ãã«ãä»ã®ãšããåºãŠããªããå¿è¡ç®¡ã€ãã³ããæžããããšããã³ã¹ããŸã 匷ããªãããæççãªã©ä»ã®æ©æµãæåŸ ããŠãã€ã«ããªçšéã§ç¶ããããšãããã©ã³ã¹ã¯åããããã
è³ã«ããããã¯æ¬åœãïŒææ°ã®DHA詊éšïŒ
ãããŸã§å¿èã®è©±ãããŠãããã©ããéã¯è³ã«ããããããèšãããããããããã£ã¡ãæåŸ ããŠãã£ãã·ã¥ãªã€ã«ã飲ãã§ãã人ã®ã»ããå€ããããããªãã
ããã«ã2026幎ã«å ±åãããã°ããã®è©Šéšããããèªç¥çãªã¹ã¯ãæã€55ã80æ³ã®365人ããè»é¡ç±æ¥ã®DHA2,000mg/æ¥ãšãã©ã»ãã«åããŠã2幎é远ããããäºéç²æ€ã®RCTã ïŒeBioMedicine 2026ïŒãããšããšãªã¡ã¬3ãå°ãªã人ã°ãããéããŠããŠãçŽåæ°ã¯ã¢ã«ããã€ããŒã«ãªããããAPOE4éºäŒåãæã£ãŠããããã¡ã°ãå¹ããããªéå£ãšãã£ãŠããã
çµæã¯ã©ãã ã£ãããèµ€è¡çã®ãªã¡ã¬3ã¯4.9%ãã11%ãŸã§äžãããè³ã®åšããæºãã髿¶²ã®DHAãå幎ã§17%å¢ããããµããªã¯ã¡ãããšè³ãŸã§å±ããŠããã
ããã§ãã2幎åŸã®èšæ¶ãèªç¥æ©èœããè³ã®æµ·éЬïŒèšæ¶ã®äžæ¢ïŒã®å€§ãããããã©ã»ããšå·®ãã€ããªãã£ããå±ããã®ã«ãåããªãã£ãã
ç ç©¶è ã®èŠç«ãŠã¯ããã ããµããªããã³ãšè¶³ãã ãã§ã¯å¹ããªããå°äžæµ·ã®äººãã¡ã§ããªã¡ã¬3ãå€ã人ã»ã©é ãã¯ã£ããããŠãããã®ã¯æ¬åœã ãã圌ãã¯éãé£ã¹ãŠãããåããŠã人ãšäŒããã¹ãã¬ã¹å°ãªãæ®ãããŠããããã®æµãã®äžã§ãããªã¡ã¬3ãæŽ»ãããçæŽ»ãã¬ã¿ã¬ã¿ãªäººã«ãµããªã ãè¶³ããŠããæµ·ã«äžæ»Žããšããããšã ã
å±ãéã¯å¿ èŠæ¡ä»¶ã§ãã£ãŠãå忡件ã§ã¯ãªããè³ã®è©±ã«ãªããšãå±ããããšã«äœãäžç·ã«ãã£ãŠããããŸã§å¹ããŠããããšããããšã ãšæãã
èªåã¯ã©ãããŠããã
ãããçç±ã¯ãèã ã£ãã
倿¥èšºå¯ã®åéã«èããšã£ãŠãå¿èãäžç¬ãé£ã¶ãæãã«æ°ã¥ããã®ãæåã ã£ããæå€åçž®ïŒè»œãäžæŽèïŒã ã
å æé¢ä¿ã¯æ£çŽããããªããã¹ãã¬ã¹ãããããªãããã«ãã§ã€ã³ãããããªãããã 倧äºããšã£ãŠããµããªã§ã®æåã¯ãããã飲ãã®ããããããæ²»ã£ããä»ã¯éãé£ã¹ãããšã§è£ã£ãŠããã
ã¡ãªã¿ã«ãé£äºããã®ãªã¡ã¬3æåã§äžæŽèãªã¹ã¯ãäžãããšãã質ã®é«ããšããã³ã¹ã¯ä»ã®ãšãã確ç«ãããŠããªãããããè€æ°ã®ååãã³ããŒãç ç©¶ã®çµ±åè§£æã§ã¯ãè¡äžãªã¡ã¬3æ¿åºŠãé«ã人ã»ã©AFãªã¹ã¯ãäœããšããçµæãåºãŠããã
ãµããªã®é«çšéæäžãšãé£äºããèªç¶ã«ãšãéã¯ãäœãžã®å
¥ãæ¹ãããããéãããµããªã®å¹ãã¯ã飲ãéãããããå±ãéãã§æ±ºãŸãããšãã話ã以äžã®ã¯ã¬ã¢ãã³ã®èšäºã§ãæžããã
ãµã±ããšããªã©ã®èµ€ãæµ·ç£ç©ã«ã¯ããã¿ãã³Eã»ã¢ã¹ã¿ããµã³ãã³ã»ã»ã¬ã³ãšãã£ã倩ç¶ã®æé žåç©è³ªãäžç·ã«å«ãŸããŠãããé žåãããããªã¡ã¬3ããé žåãããããªã¡ã¬3ããæé žåç©è³ªãšã»ããã§æããããšãŠãçã«ããªã£ãŠãããšæãããµããªåäœã§ã¯åçŸãã«ããéšåã ã
ãã£ãã®è³ã®è©Šéšã§ããµããªã ãè¶³ããŠãåããªããã ã£ãã®ãããã¶ãåãããšã ãéãé£ã¹ããšããã®ã¯ããªã¡ã¬3ã ãã§ãªãããã®åšãããšäœã«å ¥ããŠããã
ã ãããµããªãšé£äºããã®æåã¯ãåããŠèããã»ããããã
ãããæ®éã®äººã¯ã©ãããã°ãããïŒãªã¡ã¬3ã®å®è·µã¬ã€ãïŒ
ãªã¡ã¬3ã®æççäœçšèªäœã¯å€ãã®ç ç©¶ã§ç¢ºèªãããŠããŠãæ ¢æ§çãªççã¬ãã«ãé«ã人ã»ã©æ©æµãåããããå¯èœæ§ã¯ãããå¿æ¿çްåãªã¹ã¯ãšã®ãã©ã³ã¹ãèãããšãäžè¬ã®äººã«ãšã£ãŠã®çŸå®çãªèœãšãã©ãããèŠããŠããã
â ãŸãèªåã®æ°å€ã枬ã
飲ãã飲ãŸãªããã§æ©ãã§ããæéããã¡ã°ããã£ãããªãããªã¡ã¬3ãèªåã«ãšã£ãŠæå³ããããã©ãããç¥ããããªããå¥èšºã®ã€ãã§ã«é«æåºŠCRPïŒhs-CRPïŒãšäžæ§èèªã远å ã§æž¬ã£ãŠã¿ãã
hs-CRPã¯äœå ã®ççã¬ãã«ãåæ ããããŒã«ãŒã ã2019幎ã®ACC/AHAã¬ã€ãã©ã€ã³ïŒäžæ¬¡äºé²ïŒã§ã¯ãhs-CRPã2.0 mg/L以äžã®å Žåãå¿è¡ç®¡ãªã¹ã¯ãããã«é«ãŸãããšããŠãããæ ¢æ§çã«ãããè¶ ããŠãã人ã¯ãæçççãªã¢ãããŒããæ€èšãã䟡å€ãããã
CRPã¯ææçãæ¥æ§ççã§ãäžããã®ã§ãäœèª¿ããããšãã«æž¬ãã®ãã³ããå¥åº·èšºæã®ãªãã·ã§ã³ã§è¿œå ã§ããããšãå€ãã幎ã«1ã2åæž¬ãã°ååã ãäžæ§èèªã150mg/dL以äžã®äººã¯ãããã ãã§ãªã¡ã¬3ïŒç¹ã«EPAïŒã®æ©æµãåããããå±€ã«ãªãã
â¡ é£äºãå ã«æ¹åãã
ãµããªããå ã«ããããšãããããšèªåã¯æã£ãŠããã
çŸä»£ã®é£ç掻ã§ã¯ãªã¡ã¬6ïŒãµã©ãæ²¹ã»å€§è±æ²¹ã»ã³ãŒã³æ²¹ã»æãç©ïŒã®æåãå€ãããŠããªã¡ã¬6:ãªã¡ã¬3æ¯ã15ã25:1ãŸã§éããŠãããçæ³ã¯4:1以äžããµããªã§ãªã¡ã¬3ããè¶³ããããããµã©ãæ²¹ã»æãç©ã»ã³ã³ããæ£èããæžãããã»ãããæ¯çã¯æ©ãåããå¥åº·ã¯ããŸãåŒãç®ã
éã¯é±3å以äžãééïŒã€ã¯ã·ã»ãµãã»ãµã³ãã»ã¢ãžïŒãäžå¿ã«ãå ç±ã§EPA/DHAã¯20ã30%倱ãããã®ã§ãåºèº«ã»æ°Žç ®çŒ¶ïŒæ±ããšïŒã»èžãæçãå¹ççã ã
⢠ãµããªã䜿ããªããã©ãã«ãèªã
äžæŽèã®æ¢åŸããªããå¿è¡ç®¡ãªã¹ã¯ãäœã人ã«ãšã£ãŠããµããªã§1ã2g/æ¥ã®EPA+DHAããšãã®ã¯çŸå®çãªéžæè¢ã ãšæãã
ãã ãåžè²©ã®ãã£ãã·ã¥ãªã€ã«ã¯ã©ãã«ã®èªã¿æ¹ãç¥ããªããšã»ãŒæå³ããªããããã£ãã·ã¥ãªã€ã«1000mgããšå€§ããæžããŠãã補åã§ããè£é¢ãèŠããšEPA+DHAã300mgããå ¥ã£ãŠããªããã®ãããªãå€ããæ®ãã®700mgã¯ä»ã®èèªé žã§ãå¿è¡ç®¡ãžã®å¹æãæåŸ ã§ããæåã§ã¯ãªãã
確èªãããã€ã³ãã¯3ã€ã
è£é¢ã®æå衚ã§EPAãšDHAã®ãmgæ°ãã確ããããåèšã§1æ¥1ã2gã«ãªãããã«èšç®ãã
æ²¹ã®åœ¢æ ã確ãããããrTGïŒåãšã¹ãã«åããªã°ãªã»ãªãïŒåããŸãã¯ãTGåããåžåçã®ç¹ã§æå©ããEEïŒãšãã«ãšã¹ãã«ïŒåãã¯å®ããé£äºãšäžç·ã§ãªããšåžåãèœã¡ã
第äžè èªèšŒïŒIFOSãGOEDãªã©ïŒã®æç¡ã確ããããé žåææšãå ¬éããŠããã¡ãŒã«ãŒãªãããªãå®å¿
ãªã¡ã¬3ã¯é žåããããèã§ãå®ããã®ã ãšéå°åããé žåèãããã±ãŒã¹ããããé žåãããªã¡ã¬3ã¯ãããäœã«æªãå¯èœæ§ãææãããŠãããä¿¡é Œã§ããã¡ãŒã«ãŒããè²·ãã®ãçµå±ãã¡ã°ãå®å šã ã
éå°ãããå·èµåº«ã§ä¿ç®¡ãçŽå°æ¥å ã¯è«å€ã2ã3ãæã§é£²ã¿åãã
⣠飲ãŸãªãã»ãããã人ããã
å šå¡ã«ãªã¡ã¬3ãè¯ãããšãã話ã§ã¯ãªãã
ãã§ã«çºäœæ§ã®å¿æ¿çްåãææãããŠãã人
é«éœ¢ã§å¿äžå šããã£ãŠãå®éæã®èãé ã人
ã¯ã«ãã¡ãªã³ãDOACãæè¡å°æ¿è¬ã飲ãã§ãã人
è¿ã ãæè¡ãææ¯ã»ã€ã³ãã©ã³ãã®äºå®ããã人
ãã®ãããã«åœãŠã¯ãŸã人ã¯ãèªåã®å€æã§ãµããªãè¶³ãåã«ã䞻治å»ã«ãéæ²¹ãµããªãèªåã¯é£²ãã§å€§äžå€«ãããš1åèããŠã»ãããå ã®O'Keefeã®ã諞åã®å£ãã®è©±ã¯ããããã人ãã¡ã«ç¹ã«å¹ããŠããã
PISCESã¯éææ£è ã®è©±ãå¥ã®è©Šéšã¯äžæ§èèªãé«ã人ã®è©±ãè³ã®è©Šéšã¯ãçæŽ»ãæŽã£ãŠããªãé«ãªã¹ã¯ã®äººã®è©±ã詊éšããšã«ã䞻圹ãããããèªåããã®äž»åœ¹ãšåãéå£ã«ããã®ããããã5ç§èããŠãã飲ããã©ããæ±ºããã
†ã¯ãªã«ãªã€ã«ãšããéžæè¢
æè¿ã¯ã¯ãªã«ãªã€ã«ïŒå極ãªãã¢ãããæœåºãããªã¡ã¬3ïŒã«ã泚ç®ããŠãããããã£ãã·ã¥ãªã€ã«ã®äžäœäºæããšèšã人ãããããªã³è質ãå€ãå«ãã®ã§åžåçãé«ããé žåã«åŒ·ãããšããããžãã¯ã ã
ãã ãããŒã¿ã®æ¹ã¯ãŸã 決çããŠããªããã¯ãªã«ãªã€ã«ã¯ãªã³è質ãçŽ4å²ãããªã°ãªã»ãªããçŽ4å²ã®æ··åã§ã補åã«ãã£ãŠãã©ã€ãã倧ãããæ¯èŒè©Šéšã§ã¯ãåããããããã¯ãªã«ãããæå©ããäž¡æ¹ããããäžäœäºæããšèšãåããã»ã©ã®ãšããã³ã¹ã¯ãããŸã®ãšãããªãã
èªåã¯æè¿ã²ã£ãã詊ããŠããã詊ããªããšããããªããããæå€åçž®ã§äžåºŠãµããªããããŠãéã§è£ãçæŽ»ãç¶ããŠãããã¯ãªã«ãªãéããããããªãããšããæ·¡ãæåŸ ã§å幎ããã飲ãã§ã¿ãŠãããä»ã®ãšããèã¯æ®éãæ°ã®ãããããããªãããé¢ä¿ãªãã®ãããããªãã
éžæè¢ãšããŠé ã®é ã«çœ®ããŠãããããã§ããã確信ããããããããªãããšããã®ãèªåã®çŸåšå°ã ã
ãŸãšããšãèªåããã£ãŠããããš
èªåã¯ãµããªã§ã®æåããããä»ã¯ééãé±3å以äžé£ã¹ãããšã§è£ã£ãŠãã
ãµã©ãæ²¹ã»æãç©ãæžãããŠããªã¡ã¬6:ãªã¡ã¬3æ¯ãæèãã
ãµããªã¯è³ãŸã§ã¯å±ããã§ããçæŽ»ããšæŽããªããšè³ã«ã¯å¹ããªãã£ãïŒ2026幎ã®DHA詊éšïŒ
æè¿ã¯ã¯ãªã«ãªã€ã«ãã²ã£ãã詊ããŠãããå幎çµéãä»ã®ãšããèã¯æ®é
ãµããªã䜿ããªãä¿¡é Œã§ããã¡ãŒã«ãŒã§ãã©ãã«è£é¢ã®EPA+DHAåèšmgæ°1æ¥1ã2gãç®å®ã«ãã
å¿æ¿çްåã®æ¢åŸãå¿è¡ç®¡çŸæ£ãæååºè¬ã䜿ã£ãŠãã人ã¯ãé«çšéã®ãªã¡ã¬3ãèªå·±å€æã§å§ããªã
hs-CRPãšäžæ§èèªã幎ã«1ã2åãã§ãã¯ããŠãèªåã®ççã¬ãã«ãææ¡ããŠãã倿ãã
ãå¹ããã©ãããã§ã¯ãªããèªåã«ãšã£ãŠæå³ãããæèãã©ãããã§æ±ºãã
ãããŸã§èªãã§ãã ãã£ãŠãããããšãããããŸããã
圹ã«ç«ã£ãããã¹ããããããããšããããå±ã¿ã«ãªããŸãã
èªåã®äœã§ã詊ããå¥åº·ã®è©±ããããããªããŒãã§ãæ°æ¥ã«1æ¬ãããåºããŠããŸãããã²ãã©ããŒããŠããããšå¬ããã§ãã
ãã£ãšæ·±ãç¥ãããæ¹ãžïŒé¢é£èšäºïŒ
飲ããã©ããã¯ãçµå±ãèªåãé«ãªã¹ã¯åŽããã§æ±ºãŸããŸããæ°å€ã®æž¬ãæ¹ãããèªåãå®éã«ã©ã®ãµããªããããŠäœãæ®ããããŸã§ãå€æã®ææã«ãªã3æ¬ã§ãã
⌠ãã£ãã·ã¥ãªã€ã«ã®æ¬¡ã«ãçµå±ãªã«ãæ®ããã
ãªã¡ã¬3ãšä¹³é
žèããããŠã4ã€ã ã飲ãã§ãããµããªã®è©±ïŒã¡ã³ããŒéå®ïŒ
ãã®èšäºã§ãã£ãã·ã¥ãªã€ã«ããããèªåããä¹³é
žèããããŠãæçµçã«æ¯æ¥é£²ãã§ããã®ã¯4ã€ã ãããããåºæºãšãæ®ããåºæºãå
šéšåºããŠããŸãã
⌠å¥èšºãªãŒã«Aã§ãèŠéãæ€æ»ãå
šéšãŸãšããå
CRPã»ApoBã»ãã§ãªãã³ãå«ããå¥èšºã®æšæºé
ç®ã§ã¯æŸããªããªã¹ã¯ãã远å ã§æž¬ãã¹ãæ€æ»ãšæ°å€åºæºã§ãŸãšããŠããŸãã
⌠3幎飲ã¿ç¶ãããµããªã«ãå»è
ãæºããã 話
ãªã¡ã¬3ã«éããããµããªã®ãçµå±ã©ã£ã¡ãªãã åé¡ãã¯ç¹°ãè¿ãèµ·ããŸããã¿ãŠãªã³ã§åãå£ã«ã¶ã€ãã£ãèšé²ã§ãã
ã¡ã³ããŒã·ãããDr.ãããã©ããã®ãç¥ãã
ã¡ã³ããŒã·ãããDr.ãããã©ãããéå¶ããŠããŸããXã»ç¡ænoteã§ã¯åºããªããããäžæ®µèžã¿èŸŒãã è©±ãæžããŠããŸãã
- çµå¶è
ã®äž»æ²»å»ãšããŠã倿¥ã§å®éã«è©±ããŠããå
容
- è«æãèªã¿ãªããèªåã®äœã§è©Šãããå¹ããã»å¹ããªãã£ãèšé²
- æ€æ»æ°å€ã®èªã¿æ¹ããµããªã»è¬ã®éžã³æ¹
- ã¡ã³ããŒéå®ã®æ²ç€ºæ¿Q&A
æé¡1000åã§å šèšäºèªã¿æŸé¡ã§ããåããªãã£ããããè§£çŽã§ããŸããæ°ã«ãªã£ãæ¹ã¯ãèŠããŠã¿ãŠãã ããã
â»æ¬èšäºã¯äžè¬çãªå¥åº·ã»å»åŠæ å ±ã®æäŸãç®çãšãããã®ã§ãããç¹å®ã®å人ã«å¯Ÿãã蚺æã»æ²»çã»å»åŠçå©èšãè¡ããã®ã§ã¯ãããŸãããå¥åº·äžã®æžå¿µãããå Žåã¯ãå¿ ãå»çæ©é¢ãå蚺ããŠãã ãããèšäºã®æ å ±ã«åºã¥ãè¡åã®çµæã«ã€ããŠã¯ãçè ã¯è²¬ä»»ãè² ããããŸãã
ð Lok CE, Farkouh M, Hemmelgarn BR, et al. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. *N Engl J Med*. 2026;394(2):128-137. PMID: 41201837.
ð Gencer B, Djousse L, Al-Ramady OT, et al. Effect of Long-Term Marine Omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. *Circulation*. 2021;144(25):1981-1990. PMID: 34612056.
ð Westra J, Tintle N, Harris WS, O'Keefe JH, et al. Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 34 Trials including 114,326 Individuals. *medRxiv*. 2025. doi: 10.64898/2025.12.14.25342167.ïŒãã¬ããªã³ãã»èè
é ã¯èŠå確èªïŒ
ð O'Keefe EL, O'Keefe JH, Tintle NL, et al. Omega-3 and Risk of Atrial Fibrillation: Vagally-Mediated Double-Edged Sword. *Prog Cardiovasc Dis*. 2025;91:3-9. PMID: 39617283.
ð O'Keefe EL, O'Keefe JH, Tintle NL, Franco WG, Westra J, Harris WS. Associations Between Plasma Omega-3 and Fish Oil Use With Risk of Atrial Fibrillation in the UK Biobank. *J Am Heart Assoc*. 2025;14(24):e043031. PMID: 41368832.
ð Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. *Circulation*. 2019;140(11):e596-e646. PMID: 30879355.
ð Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. *Lancet*. 2023;401(10384):1293-1301. PMID: 36893777.
#å¥åº· #è«æè§£èª¬ #ãªã¡ã¬3 #ãã£ãã·ã¥ãªã€ã« #å¿è¡ç®¡çŸæ£